Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text: Dr. Ramsey is leading a study funded by the National Cancer Institute, or N.C.I., to assess the feasibility of using multi-cancer detection tests.
Simplified Text: Dr. Scott Ramsey is leading a study funded by the National Cancer Institute (NCI) to evaluate the feasibility of multi-cancer detection tests.
Confidence Score: 1.000
Claim Maker: The author
Context Type: News Article
Context Details: { "person": "Dr. Scott Ramsey", "organization": "National Cancer Institute" }
Subject Tags: Health Science Cancer
UUID: 9896938e-2cd7-42a5-9e96-4a076642d145
Vector Index: ✗ No vector
Created: September 25, 2026 at 1:05 AM (2 weeks ago)
Last Updated: September 25, 2026 at 1:05 AM (2 weeks ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://nytimes.com/2026/09/23/well/fda-cancer-blood-test-galleri-grail.html

F.D.A. Advisory Panel Endorses Controversial Cancer Blood Test

Completed News

5 claims

2 weeks ago

https://nytimes.com/2026/09/23/well/fda-cancer-blood-test-galleri-grail.html

An FDA advisory committee recommended approval for Grail's Galleri blood test, designed to detect various cancers early, despite concerns from doctors about its efficacy and lack of data showing reduced cancer deaths. The test has been available since 2021, but experts warn of risks like overdiagnosis and false positives.

FDA Cancer Screening Blood Tests Medical Technology Health Policy Oncology Grail Galleri

Similar Claims (5)

Other claims identified as semantically similar to this one.

Philip Castle, the director of the cancer prevention division at the N.C.I., said during the meeting that the test’s ability to detect cancers in the early stages, “where intervention matters the most... 1.000

Simplified: Philip Castle, director of the NCI's cancer prevention division, said during the FDA advisory meeting that the Galleri test's ability to detect early-...

2 weeks ago
An advisory committee to the Food and Drug Administration recommended on Wednesday that the agency approve a blood test designed to detect various cancers in the early stages, despite concerns among d... 1.000

Simplified: On September 23, 2026, an FDA advisory committee recommended that the agency approve the Galleri blood test, which is designed for early cancer detect...

2 weeks ago
Hundreds of thousands of people have taken a Galleri test, including 117,000 in the first half of this year. 1.000

Simplified: In the first half of 2026, 117,000 people took a Galleri test, not including those in research studies.

2 weeks ago
The test performed poorly in detecting cancers in two large studies. 1.000

Simplified: Grail's multi-cancer blood test performed poorly in detecting cancers in two large studies.

2 weeks ago
But the company spent millions successfully lobbying for legislation that would authorize Medicare to cover the test beginning in 2028 if the F.D.A. approves it. 1.000

Simplified: Grail spent millions successfully lobbying for legislation that would authorize Medicare to cover the Galleri test starting in 2028, contingent on FDA...

2 weeks ago